Aldebaran Financial Inc. lowered its stake in Amgen, Inc. (NASDAQ:AMGN) by 5.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,892 shares of the medical research company’s stock after selling 498 shares during the period. Aldebaran Financial Inc.’s holdings in Amgen were worth $1,359,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. TrimTabs Asset Management LLC grew its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 288 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its position in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 5 shares during the last quarter. Phocas Financial Corp. bought a new position in Amgen in the second quarter valued at about $110,000. Omnia Family Wealth LLC grew its position in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after acquiring an additional 147 shares during the last quarter. Finally, Grove Bank & Trust grew its position in Amgen by 87.4% in the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after acquiring an additional 341 shares during the last quarter. Institutional investors own 78.62% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $177.04 on Friday. Amgen, Inc. has a 12 month low of $145.12 and a 12 month high of $191.10. The company has a market capitalization of $130,070.00, a PE ratio of 14.10, a PEG ratio of 2.57 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period last year, the firm posted $3.02 earnings per share. The business’s revenue for the quarter was down .7% on a year-over-year basis. sell-side analysts anticipate that Amgen, Inc. will post 12.66 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.98%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 41.55%.

Amgen declared that its board has approved a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

A number of research analysts have issued reports on AMGN shares. Oppenheimer reiterated a “buy” rating and issued a $203.00 target price on shares of Amgen in a research report on Friday, October 6th. Mizuho reiterated a “buy” rating and issued a $198.00 target price on shares of Amgen in a research report on Friday, October 6th. Cann reiterated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Bank of America lifted their target price on Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Finally, Jefferies Group reiterated a “buy” rating and issued a $200.00 target price on shares of Amgen in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Amgen currently has a consensus rating of “Hold” and a consensus price target of $190.22.

In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the transaction, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at $9,921,223.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 8,575 shares of company stock worth $1,509,339 over the last three months. Insiders own 0.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amgen, Inc. (AMGN) Position Lowered by Aldebaran Financial Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/16/amgen-inc-amgn-position-lowered-by-aldebaran-financial-inc.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related stocks with our FREE daily email newsletter.